Thermo Fisher Scientific Inc. $TMO Stock Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% in the 3rd quarter, Holdings Channel reports. The firm owned 22,311 shares of the medical research company’s stock after selling 1,503 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $15,061,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Corient Private Wealth LP bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific in the second quarter valued at about $1,974,561,000. Bank of America Corp DE bought a new position in Thermo Fisher Scientific in the second quarter valued at about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Thermo Fisher Scientific by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after acquiring an additional 22,827 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.5%

Shares of TMO traded up $10.42 during trading hours on Tuesday, hitting $689.80. 1,820,982 shares of the stock were exchanged, compared to its average volume of 2,253,203. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $704.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business has a 50-day moving average of $638.93 and a 200-day moving average of $549.90. The firm has a market capitalization of $255.05 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TMO. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. BMO Capital Markets lowered shares of Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. CLSA assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 target price on the stock. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Finally, Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research note on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $654.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.